Guardant Health struck a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its oncology testing platform with Zephyr’s machine‑learning analytics. The collaboration aims to speed discovery of genomic biomarkers for drug development, therapy selection and response monitoring. Guardant said the work will be integrated into its Infinity AI capabilities and will support biopharma partners by improving predictive models of targeted therapy response. Financial terms were not disclosed. Guardant co‑CEO Helmy Eltoukhy emphasized that melding high‑quality molecular datasets with advanced analytics is a step toward realizing precision oncology at scale.